Obrenovich Mark E, Jaskiw George E, Zhang Renliang, Willard Belinda, Donskey Curtis J
Pathology and Laboratory Medicine Service; Louis Stokes Cleveland Department of Veterans Affairs Medical Center; Cleveland, Ohio.
Research Service; Louis Stokes Cleveland Department of Veterans Affairs Medical Center; Cleveland, Ohio.
Pathog Immun. 2019 Mar 14;4(1):85-103. doi: 10.20411/pai.v4i1.284. eCollection 2019.
Urinary levels of small molecules generated by the gut microbiota (GMB) constitute potential biomarkers for the state of the GMB. Such metabolites include numerous small phenolic molecules linked to anaerobic bacteria, particularly species. Due to multiple technical challenges, however, the relationship between these chemicals and the GMB remains poorly characterized. Improved, high-performance liquid chromatography-mass spectrometry (LC-MS)-based metabolomic analysis can now reliably separate and quantify low levels of multiple small phenolic molecules and their structural isomers.
CF-1 (female mice) were treated over 2 consecutive days with either i) vehicle, ii) one of 2 different antibiotic regimens (clindamycin or piperacillin/tazobactam) known to inhibit intestinal anaerobes and promote colonization by and other pathogens or iii) an antibiotic (aztreonam) that suppresses facultative Gram-negative bacteria but not or anaerobes and does not promote pathogen colonization Urine collected 24 hours after the last treatment was analyzed by LC-MS.
We identified over 25 compounds, many of which had not been previously reported in mouse urine. Eleven small phenolic molecules showed significant antibiotic-related changes. Urinary levels of the hydroxyphenylpropionic acids were suppressed by clindamycin and pipera-cillin/tazobactam treatment, but were elevated in aztreonam-treated mice. In addition, aztreonam treatment was associated with elevated levels of the dihydroxyhydrocinnamic acids.
Profiles of differential changes in urinary small phenolic molecules may provide an index of anaerobic bacterial species in the GMB and could prove useful in monitoring susceptibility to overgrowth of pathogens such as .
肠道微生物群(GMB)产生的小分子尿液水平构成了GMB状态的潜在生物标志物。这些代谢物包括许多与厌氧菌相关的小分子酚类分子,特别是某些物种。然而,由于多种技术挑战,这些化学物质与GMB之间的关系仍未得到充分表征。基于高效液相色谱-质谱(LC-MS)的改进代谢组学分析现在可以可靠地分离和定量低水平的多种小分子酚类分子及其结构异构体。
连续2天对CF-1雌性小鼠进行以下处理:i)赋形剂;ii)已知可抑制肠道厌氧菌并促进某些病原体(如[具体病原体名称缺失])定植的两种不同抗生素方案(克林霉素或哌拉西林/他唑巴坦)之一;iii)一种抑制兼性革兰氏阴性菌但不抑制某些病原体或厌氧菌且不促进病原体定植的抗生素(氨曲南)。在最后一次治疗后24小时收集尿液,通过LC-MS进行分析。
我们鉴定出超过25种化合物,其中许多以前未在小鼠尿液中报道过。11种小分子酚类分子显示出与抗生素相关的显著变化。羟基苯丙酸的尿液水平在克林霉素和哌拉西林/他唑巴坦治疗后受到抑制,但在氨曲南治疗的小鼠中升高。此外,氨曲南治疗与二羟基氢化肉桂酸水平升高有关。
尿液中小分子酚类分子的差异变化谱可能提供GMB中厌氧细菌种类的指标,并可能有助于监测对某些病原体(如[具体病原体名称缺失])过度生长的易感性。